← Eichor
Study identifier: NCT06052254 Synced from ClinicalTrials.gov · July 28, 2026
● Recruiting

Dexmedetomidine Transdermal Systems (DMTS) Treatment for Agitation Associated With Dementia of the Alzheimer's Type

Condition: Agitation  ·  Sponsor: Teikoku Pharma USA, Inc.

PhasePhase 2
Planned participants150
Who can joinAll sexes, N/A to no upper limit
Healthy volunteersNo

About this study

The primary objective of this study is to evaluate the efficacy of DMTS on frequency and severity of agitation associated with dementia of the Alzheimer's type, compared with placebo.

This description comes directly from the study's public registry record.

Talk to the study team

Tami Ujiie  ·  408-501-1822  ·  tujiie@teikokuusa.com

Always discuss trial participation with your own doctor first.

Locations (8)

Arrow Clinical TrialsDaytona Beach, Florida, United StatesRecruiting
Personal Physician CareDelray Beach, Florida, United StatesRecruiting
Global Medical Institutes Florida LLCMiami, Florida, United StatesRecruiting
Miami Jewish HealthMiami, Florida, United StatesRecruiting
Professional Health Care of Pinellas, LLCSt. Petersburg, Florida, United StatesRecruiting
Elixia MA, LLCSpringfield, Massachusetts, United StatesWithdrawn
VitalixWorcester, Massachusetts, United StatesRecruiting
BioBehavioral HealthToms River, New Jersey, United StatesWithdrawn

Follow this study

Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.

We email about this public record only. Unsubscribe anytime with one click. Never medical advice.

Is this your study? This page was generated automatically from the public registry record. Sponsors can claim it — free — to add branding and verified contact routing. Claim this page →

This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.

Source record: clinicaltrials.gov/study/NCT06052254